Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes. (Q52022309)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 March 2006

Language	Label	Description	Also known as
English	Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes.	scientific article published on 29 March 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

protein evolution

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

author name string

Morito Kurata

1

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Maki Hasegawa

2

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Yasunori Nakagawa

3

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Shinya Abe

4

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Kouhei Yamamoto

5

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Kenshi Suzuki

6

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Masanobu Kitagawa

7

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

publication date

29 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Experimental and Molecular Pathology

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

81

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

3

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

249-254

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Minimally differentiated acute myeloid leukemia (AML M0): clinico-biological findings of 29 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Acute myeloid leukemia in the elderly: biology and therapeutic strategies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Expression of the multidrug resistance-associated protein in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

Bone marrow analysis of the myelodysplastic syndromes: histological and immunohistochemical features related to the evolution of overt leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2006.01.004

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YEXMP.2006.01.004

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 April 2018

http://europepmc.org/abstract/MED/16566920

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52022309&oldid=1382486593"